SCHEMBL9607902

SCHEMBL9607902

C=C(C)C(=O)Oc1ccc(-c2ccc(OC(=O)C(=C)C)cc2F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.48
KMT2A Q03164 4/20 0.44
ATM Q13315 1/20 0.44
APP P05067 5/20 0.44
CYP2C19 P33261 4/20 0.44
BACE1 P56817 1/20 0.39
GAPDH P04406 1/20 0.38
CYP2C9 P11712 3/20 0.37
CYP3A4 P08684 2/20 0.37
ERN1 O75460 1/20 0.36
PTGS1 P23219 3/20 0.36
MEN1 O00255 2/20 0.36
PTGS2 P35354 2/20 0.36
AKR1C3 P42330 2/20 0.36
AKR1C2 P52895 2/20 0.36
CYP1A2 P05177 2/20 0.36
FABP2 P12104 1/20 0.36
TSHR P16473 1/20 0.36
AKR1C4 P17516 1/20 0.36
ADRA2B P18089 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9607894 0.98 ELANE (0.47) ELANEKMT2AATMAPPCYP2C19
SCHEMBL25943727 0.97 ELANE (0.46) ELANEKMT2AATMAPPCYP2C19
SCHEMBL14987780 0.93 APP (0.46) ELANEKMT2AATMAPPCYP2C19
SCHEMBL20311934 0.93 CYP2C19 (0.53) ELANEKMT2AATMAPPCYP2C19
SCHEMBL21101681 0.93 BACE1 (0.42) ELANEKMT2AATMAPPCYP2C19
SCHEMBL12196852 0.93 CYP2C19 (0.50) ELANEKMT2AATMAPPCYP2C19
SCHEMBL18083260 0.93 ELANE (0.41) ELANEKMT2AATMAPPCYP2C19
SCHEMBL9607895 0.93 ELANE (0.47) ELANEKMT2AATMAPPCYP2C19
SCHEMBL26144160 0.93 ELANE (0.43) ELANEKMT2AATMAPPCYP2C19
SCHEMBL18194819 0.92 ELANE (0.42) ELANEKMT2AATMAPPCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 621 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12043781-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2024-07-23 US disclosed
US-12043781-B2 Liquid-crystalline medium MERCK PATENT GMBH (DE) 2024-07-23 US disclosed
EP-4400561-A1 LIQUID-CRYSTAL MEDIUM Merck Patent GmbH (DE) 2024-07-17 EP disclosed
WO-2024133363-A1 LIQUID-CRYSTAL MEDIUM MERCK PATENT GMBH (DE) 2024-06-27 WO disclosed
WO-2024132893-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2024-06-27 WO disclosed
WO-2024126567-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2024-06-20 WO disclosed
US-20240067879-A1 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-02-29 US disclosed
US-20240067879-A1 Liquid-crystal medium MERCK PATENT GMBH (DE) 2024-02-29 US disclosed
EP-3924447-B1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2024-01-24 EP disclosed
EP-4306615-A1 LIQUID-CRYSTAL MEDIUM Merck Patent GmbH (DE) 2024-01-17 EP disclosed
US-20130037745-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-02-14 US disclosed
EP-2557140-A2 Liquid-crystalline medium Merck Patent GmbH (DE) 2013-02-13 EP disclosed
US-20120326085-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-12-27 US disclosed
US-20120326085-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-12-27 US disclosed
WO-2012130380-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2012-10-04 WO disclosed
WO-2012097858-A1 POLYMERISABLE COMPOUNDS AND THE USE THEREOF IN LIQUID-CRYSTAL DISPLAYS MERCK PATENT GMBH (DE) 2012-07-26 WO disclosed
WO-2012079710-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2012-06-21 WO disclosed
WO-2012072201-A1 LIQUID-CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2012-06-07 WO disclosed
WO-2012069151-A1 LIQUID CRYSTALLINE MEDIUM MERCK PATENT GMBH (DE) 2012-05-31 WO disclosed
EP-2457975-A2 Liquid-crystalline mixtures Merck Patent GmbH (DE) 2012-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120326085-A1 LIQUID-CRYSTALLINE MEDIUM TLL1, LAS1L, LOXL1 ELANE 534/4885KMT2A 3876/4885ATM 1523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.